Navigation Links
Sequent Medical, Inc. Awarded U.S. Patent For Innovative Implant Designs Using Composite Wire Technology
Date:7/14/2015

ALISO VIEJO, Calif., July 14, 2015 /PRNewswire/ -- Sequent Medical announced today the grant by the U.S. Patent and Trademark Office of Patent No. 9,078,658, entitled "Filamentary Devices for Treatment of Vascular Defects."

This new patent – the eighth U.S. Patent granted to Sequent – covers many versions of Sequent's WEB™ Aneurysm Embolization System.  WEB is a braided implant that includes composite drawn filled tube wires, i.e., an external nitinol tube and a highly radiopaque material disposed within the tube.  Sequent's WEB Aneurysm Embolization System devices utilize this technology for Enhanced Visualization ("EV") while preserving desired mechanical properties.  WEB is braided from numerous wires, which in some cases are less than one-quarter of the diameter of a human hair.

As previously reported, the company has developed and introduced in Europe EV versions of WEB in single-layer WEB SL and SLS configurations.  In the United States, enrollment in an Investigational Device Exemption ("IDE") clinical study called WEB-IT is underway; WEB EV designs are now being implanted in the study.

"We are pleased to have achieved this important milestone in our ongoing efforts to develop our intellectual property portfolio," said Tom Wilder, President and Chief Executive Officer.  "Improving the visualization of WEB proved to be a significant engineering challenge.  EV technology is the latest demonstration of Sequent's robust innovation capability, and further extends our leadership of the intrasaccular flow disruption category.  The utility of Sequent's proprietary technology extends beyond the neurovascular field, and has the potential to address a number of unmet clinical needs."

About Sequent Medical, Inc.
Founded in 2007, Sequent Medical, Inc. (www.sequentmedical.com) is a privately held venture backed medical device company that is dedicated to the development of innovative catheter-based neurovascular technologies.  WEB Aneurysm Embolization System and VIA® Microcatheter have both received the CE mark.  The VIA has been cleared for commercial use in the United States.  In the United States, WEB is an investigational device limited by United States law to investigational use.  Sequent is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany.

About WEB Aneurysm Embolization System
Building upon the foundation of endovascular embolic coils, WEB is an intrasaccular flow disrupter that is implanted into a ruptured or unruptured intracranial aneurysm to promote rapid, peri-procedural stasis.  WEB is based upon Sequent Medical's proprietary MicroBraid™ technology, a dense mesh constructed from a large number of extremely fine wires.  Unlike conventional medical braids, MicroBraid allows for a mix of wire diameters or materials to achieve a tailored balance of compliance, porosity and profile across device sizes.

WEB enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials.  To date, WEB has been used to treat over 1,700 ruptured and unruptured aneurysms worldwide.


 


'/>"/>
SOURCE Sequent Medical, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequent Medical nombra a Mike Kleine a su junta directiva
2. Sequent Medical beruft Mike Kleine in den Aufsichtsrat
3. Sequent Medical Appoints Mike Kleine to its Board of Directors
4. Sequent Medical Announces Presentation of Compelling Long-Term Clinical Data and Commercial Release of its Next Generation WEB Product
5. Sequent Medical Announces Approval To Utilize Latest Generation WEB Devices In U.S. IDE Study
6. Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt
7. Sequent Medical annonce le démarrage dune étude IDE pour le système WEB dembolisation des anévrismes
8. Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System
9. Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark
10. New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimers Disease
11. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... ... June 13, 2019 , ... Recent lawsuits, ... with a back problem, underscore the responsibility of employers to provide reasonable accommodations ... accommodation requests are reasonable and which are not - from requests by hearing-impaired ...
(Date:6/13/2019)... , ... June 13, 2019 , ... The American Psychiatric ... director to succeed current executive director Nicholas Croce Jr., MS. The search will be ... Board of Directors, past APNA Presidents, and Council and Chapter leaders. , The job ...
(Date:6/13/2019)... ... 2019 , ... Online laser therapy education portal, Laser Therapy ... about non-invasive photobiomodulation (PBM) therapy to relieve pain. LTU will host a live ... , Also known as low-level laser therapy (LLLT), PBM was first ...
Breaking Medicine Technology:
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... ... , has announced that the final entry deadline in the 2019 competition is ... , Recognized as the world’s premier business awards program, The IBAs attract nominations ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... RN, BSN, CRNI and Charles “Charlie” Schadewald as the newest members of its ... as members of NICA’s Advisory Committee. The NICA Advisory Committee is comprised of ...
(Date:6/13/2019)... ... June 13, 2019 , ... GlycoMark, Inc. announced a new ... Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for ... SGLT-2 inhibitors are used to lower glucose levels in patients with diabetes by ...
(Date:6/12/2019)... ... June 12, 2019 , ... GlucoseZone , ... pleased to announce that LaurieAnn Scher, MS, RD, CDE GlucoseZone’s Chief Strategy ... Diabetes Educator of the Year 2019, honoring best-in-class learning and development initiatives within ...
(Date:6/12/2019)... ... June 12, 2019 , ... Learn ... get valuable advice on innovative branding and network with others in this growing ... media representatives, farmers, nutritionists, manufacturers and others who are part of the rapidly ...
Breaking Medicine News(10 mins):